title: Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.
abstract: Human immunodeficiency virus 1 (HIV-1) Rev and integrase (IN) proteins are required within the nuclei of infected cells in the late and early phases of the viral replication cycle, respectively. Here we show using various biochemical methods, that these two proteins interact with each other in vitro and in vivo. Peptide mapping and fluorescence anisotropy showed that IN binds residues 1-30 and 49-74 of Rev. Following this observation, we identified two short Rev-derived peptides that inhibit the 3'-end processing and strand-transfer enzymatic activities of IN in vitro. The peptides bound IN in vitro, penetrated into cultured cells, and significantly inhibited HIV-1 in multinuclear activation of a galactosidase indicator (MAGI) and lymphoid cultured cells. Real time PCR analysis revealed that the inhibition of HIV-1 multiplication is due to inhibition of the catalytic activity of the viral IN. The present work describes novel anti-HIV-1 lead peptides that inhibit viral replication in cultured cells by blocking DNA integration in vivo.
authors.affiliation: Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, and Department of Organic Chemistry, Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
authors.forename: Joseph
authors.initials: J
authors.lastname: Rosenbluh
authors.forename: Zvi
authors.initials: Z
authors.lastname: Hayouka
authors.forename: Shoshana
authors.initials: S
authors.lastname: Loya
authors.forename: Aviad
authors.initials: A
authors.lastname: Levin
authors.forename: Ayelet
authors.initials: A
authors.lastname: Armon-Omer
authors.forename: Elena
authors.initials: E
authors.lastname: Britan
authors.forename: Amnon
authors.initials: A
authors.lastname: Hizi
authors.forename: Moshe
authors.initials: M
authors.lastname: Kotler
authors.forename: Assaf
authors.initials: A
authors.lastname: Friedler
authors.forename: Abraham
authors.initials: A
authors.lastname: Loyter
mesh_terms: D019380:Anti-HIV Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D015195:Drug Design; D015694:Gene Products, rev / Q000737:chemistry* / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D019427:HIV Integrase / Q000737:chemistry* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism / Q000473:pathology / Q000821:virology; D010449:Peptide Mapping; D010455:Peptides / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D016662:Virus Integration / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects; D054321:rev Gene Products, Human Immunodeficiency Virus
chemical_list: D019380:Anti-HIV Agents; D015694:Gene Products, rev; D010455:Peptides; D054321:rev Gene Products, Human Immunodeficiency Virus; D019427:HIV Integrase